Diversified Trust Co increased its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) by 10.4% in the first quarter, Holdings Channel reports. The firm owned 16,421 shares of the company’s stock after buying an additional 1,546 shares during the quarter. Diversified Trust Co’s holdings in Maravai LifeSciences were worth $579,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also modified their holdings of the stock. Arcadia Investment Management Corp MI acquired a new stake in shares of Maravai LifeSciences in the 4th quarter worth $41,000. Spire Wealth Management acquired a new stake in shares of Maravai LifeSciences in the 4th quarter worth $71,000. Nkcfo LLC acquired a new stake in shares of Maravai LifeSciences in the 4th quarter worth $101,000. SG Americas Securities LLC acquired a new stake in shares of Maravai LifeSciences in the 4th quarter worth $112,000. Finally, Bayesian Capital Management LP lifted its stake in shares of Maravai LifeSciences by 22.1% in the 4th quarter. Bayesian Capital Management LP now owns 5,245 shares of the company’s stock worth $220,000 after acquiring an additional 949 shares during the period. Hedge funds and other institutional investors own 50.18% of the company’s stock.
Shares of MRVI opened at $26.78 on Thursday. The company has a 50-day simple moving average of $31.38 and a 200-day simple moving average of $34.03. The company has a quick ratio of 6.55, a current ratio of 7.14 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $6.83 billion, a PE ratio of 16.84 and a beta of 0.76. Maravai LifeSciences Holdings, Inc. has a 52-week low of $23.16 and a 52-week high of $63.55.
Maravai LifeSciences (NASDAQ:MRVI – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.11. The business had revenue of $244.30 million during the quarter, compared to the consensus estimate of $232.29 million. Maravai LifeSciences had a net margin of 25.25% and a return on equity of 96.51%. The business’s revenue was up 64.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.26 EPS. On average, research analysts anticipate that Maravai LifeSciences Holdings, Inc. will post 1.85 EPS for the current year.
Several research firms have recently commented on MRVI. Morgan Stanley reduced their target price on shares of Maravai LifeSciences from $59.00 to $54.00 and set an “overweight” rating for the company in a research note on Friday, February 25th. Robert W. Baird reduced their target price on shares of Maravai LifeSciences from $48.00 to $40.00 in a research note on Friday, May 6th.
Maravai LifeSciences Profile (Get Rating)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Read More
Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating).
Receive News & Ratings for Maravai LifeSciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Maravai LifeSciences and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
